Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 4/20 | 0.57 |
| ▸ | SYK | P43405 | 3/20 | 0.50 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.50 |
| ▸ | STK17A | Q9UEE5 | 6/20 | 0.48 |
| ▸ | STK17B | O94768 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.45 |
| ▸ | BCL6 | P41182 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 2/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10259353 | 0.88 | STK17A (0.62) | AURKASYKSTK17ASTK17BBCL6 | |
| SCHEMBL301484 | 0.88 | EGFR (0.57) | AURKASYKSTK17AEGFRJAK3 | |
| SCHEMBL303133 | 0.86 | SYK (0.49) | AURKASYKSTK17AEGFRBCL6 | |
| SCHEMBL301485 | 0.85 | AURKA (0.51) | AURKASTK17ASTK17BEGFRBCL6 | |
| SCHEMBL17915958 | 0.83 | AURKA (0.62) | AURKASYKZAP70STK17ASTK17B | |
| SCHEMBL10260237 | 0.82 | BCL6 (0.55) | AURKASYKSTK17ASTK17BEGFR | |
| SCHEMBL303236 | 0.82 | STK17A (0.62) | AURKASYKSTK17ASTK17BBCL6 | |
| SCHEMBL656192 | 0.81 | AURKA (0.69) | AURKASYKSTK17ASTK17BEGFR | |
| SCHEMBL10260236 | 0.80 | AURKA (0.52) | AURKASYKZAP70STK17ASTK17B | |
| SCHEMBL10260837 | 0.80 | SYK (0.51) | AURKASYKSTK17AEGFRJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | AURKA 745/4885SYK 59/4885ZAP70 48/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | AURKA 75/4885SYK 281/4885ZAP70 68/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | AURKA 75/4885SYK 281/4885ZAP70 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.